Dr. J. Jacques Carter Joins OncBioMune Pharmaceuticals Scientific Advisory Board

OncBioMune Pharmaceuticals (OTCMKTS:OBMP) announced the appointment of Dr. J. Jacques Carter to the Company’s Scientific Advisory Board.
As quoted in the press release:

Dr. Carter currently serves as a physician at the Beth Israel Deaconess Medical Center in Boston, MA and is an assistant professor at Harvard Medical School. From 2005 to 2014, he also served as the Medical Director of the Prostate Cancer Screening and Education Program at the Dana-Farber Cancer Institute.
Dr. Carter has held a number of clinical and administrative positions, including Medical Directorships of several local and national health care organizations. A former director of one of the major clerkships, he now serves as a teacher/advisor/mentor for students at Harvard Medical School and the Harvard School of Public Health. Dr. Carter has been active in a number of civic and community organizations, including past president of the board of Family Service of Greater Boston and past chair of the Brookline Advisory Council on Public Health. He regularly gives talks on medical and health related issues to community groups and students throughout greater Boston.
He also lectures nationally and internationally on medical and public health topics. Dr. Carter serves as a medical consultant and resource for members of the media. He is a past President of the Harvard School of Public Health Alumni Association and a current director of the Harvard Alumni Association. Dr. Carter is a founding member of the Georgetown University African American Advisory Board. He is the recipient of the 2010 Harvard Medical School/Harvard School of Dental Medicine Community Service Lifetime Achievement Award. His bio has been included in “Who’s Who in the East, “Who’s Who in Medicine and Healthcare”, Who’s Who in Science and Engineering, and “Who’s Who in America”.

OncBioMune CEO, Dr. Jonathan Head, stated:

We’re thrilled to welcome Dr. Carter to our Scientific Advisory Board. As a highly respected physician and educator, Dr. Carter brings years of highly relevant experience and adds another well informed perspective to our team. His knowledge and expertise in the field of prostate cancer is synergistic and will prove invaluable with our clinical development of ProscaVax.

Connect with OncBioMune Pharmaceuticals (OTCMKTS:OBMP) to receive an Investor Presentation.